Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific Officer, Cornelis “Kees” Melief, M.D., Ph.D., will be presenting key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online. Read more…
Co-founded with renowned immunologist Professor Caetano Reis e Sousa of the Francis Crick Institute First UK-based ATP portfolio company NEW YORK and LONDON, December 7, 2021—ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. (“Adendra”), a company that will discover and develop treatments for cancers and autoimmune diseases […]
Leucid Bio: Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods 4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, is pleased to announce a Joint Development Agreement (“JDA”) between its wholly owned subsidiary 4basebio Discovery […]
Has Kiadis Found Immunotherapy’s Killer App? In Amsterdam, there has just been a glimpse of the future of cellular medicine.
With World Cancer Day in mind this week, we want to put the spotlight on our fantastic client Masters Pharma.
